EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Acquired von Willebrand syndrome and chronic lymphocytic leukaemia/small lymphocytic lymphoma: Report of two cases and systematic review of the literature

Alexandre Butelet, Damien Roos-Weil, Antoine Rauch, Karim Maloum, Mélanie Daniel, Morgane Nudel, Camille Paris, Micha Srour, Sophie Susen, Stéphanie Poulain, Annabelle Dupont

Therapeutic Advances in Hematology · 2026-11 · 17

DOI: 10.1177/20406207261505296 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 13.11.2026. Verfasst von Alexandre Butelet und 10 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired von Willebrand syndrome (AVWS) is a rare and potentially life-threatening bleeding disorder. Chronic lymphocytic leukaemia (CLL), the most common leukaemia, and its tissue counterpart, small lymphocytic lymphoma (SLL), are characterized by clonal B-cell proliferation. Although AVWS is frequently associated with lymphoproliferative disorders, its association with CLL/SLL remains poorly characterized, and no dedicated systematic review is currently available. We aimed to provide comprehensive insights into epidemiology, pathophysiological mechanisms, diagnosis, clinical presentation and management of AVWS associated with CLL/SLL. We report two original cases of AVWS associated with CLL/SLL and conducted a systematic literature review on AVWS cases occurring in a CLL/SLL context following PRISMA guidelines to characterize clinical presentation, biological features, treatment strategies and outcomes. While autoimmune phenomena are well known to complicate CLL/SLL, only 34 cases of CLL/SLL associated with AVWS were identified between 1976 and 2026, in addition to our two original cases. Few patients were diagnosed with AVWS before or simultaneously with CLL/SLL diagnosis. Approximately one third of patients with AVWS associated with CLL/SLL had a normal activated partial thromboplastin time, supporting systematic assessment of von Willebrand factor antigen, von Willebrand factor activity and factor VIII assays in bleeding patients. Bleeding severity and treatment approach were highly heterogeneous. Limited case reports suggest that venetoclax combined with rituximab or obinutuzumab may induce sustained remission of both CLL/SLL and AVWS, although these findings remain hypothesis-generating. Published experience with ibrutinib is also limited, with no reported sustained remission. This first dedicated systematic review of AVWS associated with CLL/SLL highlights important diagnostic and therapeutic considerations for this rare complication. Early recognition of AVWS in bleeding patients with CLL/SLL may improve management and support further investigation of targeted therapies in this setting.

Zitieren

APA

Butelet, A., Roos-Weil, D., Rauch, A., Maloum, K., Daniel, M., Nudel, M., Paris, C., Srour, M., Susen, S., Poulain, S., & Dupont, A. (2026). Acquired von Willebrand syndrome and chronic lymphocytic leukaemia/small lymphocytic lymphoma: Report of two cases and systematic review of the literature. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261505296

Vancouver

Butelet A, Roos-Weil D, Rauch A, Maloum K, Daniel M, Nudel M, et al. Acquired von Willebrand syndrome and chronic lymphocytic leukaemia/small lymphocytic lymphoma: Report of two cases and systematic review of the literature. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261505296

BibTeX
@article{Butelet2026,
  author = {Butelet, Alexandre and Roos-Weil, Damien and Rauch, Antoine and Maloum, Karim and Daniel, Mélanie and Nudel, Morgane and Paris, Camille and Srour, Micha and Susen, Sophie and Poulain, Stéphanie and Dupont, Annabelle},
  title = {Acquired von Willebrand syndrome and chronic lymphocytic leukaemia/small lymphocytic lymphoma: Report of two cases and systematic review of the literature},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261505296}
}
Kostenlos starten →